Biologic properties and clinical uses of rifaximin
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Rifaximin is increasingly being used to treat acute and chronic gastrointestinal infections and disorders. The drug exerts its beneficial effect through a variety of gut-selective mechanisms involving the host intestinal microbiota. AREAS COVERED: Abstracts of all publications listed in PubMed on the topic of rifaximin are reviewed to determine their potential value in the understanding of mechanisms of rifaximin activity. The author's extensive file on the drug is also used in the review. EXPERT OPINION: Rifaximin inhibits a broad spectrum of bacteria in the bile-rich small bowel and susceptible bacteria in the aqueous colon, and alters microbial virulence and epithelial cell function. The different mechanisms of action of rifaximin potentially explain the use of the drug in widely varied diseases and syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 11×
“Low levels of PXR may be associated with activity in both Crohn’s disease and ulcerative colitis [14,15], which may explain Primary and potential mechanisms/activities Biologic and clinical effectsBioavailability HE: Hepatic encephalopathy; IBS: Irritable bowel syndrome; MIC: Minimal inhibitory concentration.”
BackgroundInfluentialActivation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 1×
“In IBS, either idiopathic or postinfectious forms, other features may be involved in the pathogenesis of the syndrome, including visceral hypersensitivity [51], gut inflammation and hormonal alterations [52], and mucosal-immune reactivity [53].”
BackgroundSmall Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396 · cited 1×
“With SIBO, there is release of gases in the intestine and bloating with associated changes in bowel function [43].”
BackgroundIncreased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
Shah, Y. M., Ma, X., Morimura, K., Kim, I., & Gonzalez, F. J. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00528.2006 · Cited by 231
Gupta, A., Dhiman, R. K., Kumari, S., Rana, S., Agarwal, R., Duseja, A., & Chawla, Y. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.017 · Cited by 202 · cited 1×
“The SIBO in hepatic encephalopathy is likely to play a role in the development of encephalopathy [34].”
BackgroundPeralta, S., Cottone, C., Doveri, T., Almasio, P. L., & Craxi, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2628 · Cited by 88 · cited 9×
“Patients with alcohol-induced cirrhosis have small bowel intestinal bacterial overgrowth (SIBO) [29-33] probably related to portal hypertension, mucosal hyperemia and alteration of motility of the small bowel.”
BackgroundInfluentialEnteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy
Infante, R. M., Ericsson, C. D., Jiang, Z.-D., Ke, S., Steffen, R., Riopel, L., Sack, D. A., & Du>Pont, H. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00322-7 · Cited by 55 · cited 1×
“The duration of TD after initiating rifaximin treatment is ~ 24 -- 32 h, while the duration of diarrhea after initiating a placebo is between 66 and 72 h [5,6,25,26].”
BackgroundSelf-citationEsposito, I. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.13.6016 · Cited by 28 · cited 8×
“Patients with alcohol-induced cirrhosis have small bowel intestinal bacterial overgrowth (SIBO) [29-33] probably related to portal hypertension, mucosal hyperemia and alteration of motility of the small bowel.”
BackgroundInfluential
Cited by
Effect of probiotics on central nervous system functions in animals and humans: a systematic review
Wang, H., Lee, I.-S., Braun, C., & Enck, P. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16018 · Cited by 334
DuPont, H. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12728 · Cited by 171
“protection against bacterial infection),(65) anti-inflammatory properties,(65) and the preservation of normal colonic flora.(66)”
BackgroundSelf-citationTandon, P., DeLisle, A., Topal, J. E., & Garcia–Tsao, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.017 · Cited by 158
Zhu, Q., Zou, L., Jagavelu, K., Simonetto, D. A., Huebert, R. C., Jiang, Z.-D., DuPont, H. L., & Shah, V. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.013 · Cited by 144
Self-citation
Metadata
- Authors
- DuPont, H. L.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-01-13
- Volume
- 12
- Issue
- 2
- Pages
- 293-302
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2060728486
- Cited by
- 44
- References
- 9
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biologic properties and clinical uses of rifaximin. https://app.cochat.ai/papers/10.1517/14656566.2011.546347
- The paper
- DuPont, H. L. (2011). Biologic properties and clinical uses of rifaximin. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2011.546347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.